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1. Introduction 
Tuberculosis (TB) is a disease also know as consumption, wasting disease, and the white 
plague, it has affected humans for centuries. Until the mid-1800s, people thought that 
tuberculosis, or TB, was hereditary. They did not realize that it could be spread from person 
to person through the air. Also, until the 1940s and 1950s there was no cure for TB. For 
many people, a diagnosis of TB was a slow death sentence 1-4. 
In 1865 a French surgeon, Jean-Antoine Villemin, proved that TB was contagious, and in 
1882 a german scientist named Robert Koch discovered the bacteria causes TB, denominated 
as Mycobacterium tuberculosis. Yet half a century passed before drugs were discovered that 
could cure TB, until then, many people with TB were sent to sanatoriums, special rest homes 
where they followed a prescribed routine every day. A breakthrough came in 1943, an 
american scientist, Selman Waksman discovered a drug that could kill TB bacteria. Between 
1943 and 1952, two more drugs were found, after these discoveries, many people with TB 
were cured and the death rate for TB in the United States dropped dramatically, and fewer 
and fewer people got TB 5.  
A global health emergency 6, 7: 
 Someone in the world is newly infected with TB bacilli every second. 
 Overall, one-third of the world's population is currently infected with the TB bacillus. 
 5-10 % of people who are infected with TB bacilli become sick or infectious at some time 
during their life.  
TB program activities, reinforced by successful chemotherapy, resulted in a pronounced 
reduction of infection and death rates. The disease became greatly controlled but it never 
quite disappeared. Then, in around 1985, cases of TB began to rise again in industrialized 
countries. Several inter-related forces drove this resurgence, including increase in prison 
populations, homelessness, injection drug use, crowded housing and increased immigration 
from countries where TB continued to be endemic. Above all, the decline in TB control 
activities and the human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) epidemic were two major factors fuelling each other in the re-emergence of TB.  
People with HIV and TB infection are much more likely to develop TB. The HIV/AIDS 
epidemic has produced a devastating effect on TB control worldwide. While one out of ten 
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immunocompetent people infected with M. tuberculosis will fall sick in their lifetimes, 
among those with HIV infection, one in ten per year will develop active TB. In developing 
countries, the impact of HIV infection on the TB situation, especially in the 20-35 age groups, 
is overwhelming. While wealthy industrialized countries with good public health care 
systems can be expected to keep TB under control, in much of the developing world a 
catastrophe awaits. In poorly developed countries, TB remains a significant threat to public 
health, as incidences remain high, even after the introduction of vaccination and drug 
treatment. The registered number of new cases of TB worldwide roughly correlates with 
economic conditions: highest incidences are seen in the countries of Africa, Asia, and Latin 
America with the lowest gross national products. Supervised treatment, including 
sometimes direct observation of therapy (DOT), was proposed as a means of helping 
patients to take their drugs regularly and complete treatment, thus achieving cure and 
preventing the development of drug resistance 5-7. 
2. Transmission and pathogenesis 
TB is spread from person through the air. When a person with pulmonary or laryngeal TB 
coughs, sneezes, speaks, or sings, droplet nuclei containing Mycobacterium tuberculosis are 
expelled into the air. Depending on the environment, these tiny particles (1-5 microns in 
diameter) can remain suspended in the air for several hours. If another person inhales air 
containing droplet nuclei, transmission may occur. The probability that TB will be 
transmitted depends on these factors 4, 5: 
 The infectiousness of the person with TB (the number of organisms expelled into the air). 
 The environment in which exposure occurred. 
 The duration of exposure and the virulence of the organism. 
The best way to stop transmission is to isolate patients with infectious TB immediately and 
start effective TB therapy. Infectiousness declines rapidly after adequate therapy is started, 
as long as the patient adheres to the prescribed regimen. Persons at the highest risk of 
becoming infected with Mycobacterium tuberculosis are close contacts, the persons who had 
prolonged, frequent, or intense contact with a person with infectious TB. Close contacts may 
be family members, roommates, friends, coworkers, or others. Data collected by CDC since 
1987 show that infection rates have been relatively stable, ranging form 21-23% for the 
contacts of infectious TB patients 6-9. Some people with infection develop TB disease. This 
disease develops when the immune system cannot keep the tubercle bacilli under control 
and the bacilli begin to multiply rapidly. The risk that TB disease will develop is higher for 
some people than for others 3, 10-12. Among contacts of persons with drug-resistant TB, 
infection rates seem to be similar. However, because they may have a poor response to 
treatment persons with drug-resistant disease are often infectious for longer periods and 
therefore have the potential to infect more contacts 10-13.  
Extra pulmonary TB is rarely contagious; however, transmission from extrapulmonary sites 
has been reported during aerosol-producing procedures, such as autopsies and tissue 
irrigation 14-16. 
3. Pathogenesis  
The tubercle bacilli that alveoli are ingested by alveolar macrophages, the majority of these 
bacilli are destroyed or inhibited. A small number multiply intracellulary and are released 
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when the macrophages die. These bacilli can spread through the lymphatic channels to 
regional lymph nodes and then through the bloodstream to more distant tissues and organs, 
including areas in which TB disease is most likely to develop: the apices of the  lung, the 
kidneys, the brain, and bone.  Extracellular bacilli attract macrophages form the 
bloodstream. The immune response kills most of the bacilli, leading to the formation of a 
granuloma. At this point the person has TB infection, which can be detected by using the 
tuberculin skin test. It may take 2-10 weeks for the infected person to develop a positive 
reaction to the tuberculin skin test. Immune responses soon develop to kill the bacilli. 
Within 2-10 weeks after infection, the immune system is usually able to halt the 
multiplication of the tubercle bacilli, preventing further spread 4, 17-19. 
In persons infected with Mycobacterium tuberculosis  but that don’t  have TB disease cannot 
spread the infection to other people. TB infection in persons who does not have TB disease 
is not considered a case of TB and referred to as ¨latent TB infection¨. In some persons, TB 
bacilli overcome the defenses or the immune system and begin to multiply, resulting in 
the progression from TB infection to TB disease.  This process may occur soon after or 
many years after infection. Some study demonstrated that approximately 5% of person 
who have been infected with Mycobacterium tuberculosis  will develop TB disease in the 
first year or two after infection and another 5% will develop disease some time later in 
life. Recent infection (with the past 2 years) with Mycobacterium tuberculosis is therefore an 
important risk factor for progression to TB disease and in approximately 10% of persons 
with normal immune system who are infected with Mycobacterium tuberculosis , TB disease 
will develop at some point 5-7.  
Some medical conditions increase the risk that TB infection will progress to disease. Some 
studies suggest that the risk  is mayor in inmmunosuppressed patients, for example persons 
with Diabetes mellitus, prolonged therapy with corticosteroids, immunosuppressive 
therapy, certain types of cancer,  severe kidney disease, injection of illicit drugs, and 
infection with Human Immunodeficient  Virus (HIV) 2,3,12. 
TB disease most commomly affects the lung,  73% of TB cases are exclusively pulmonary, 
and however, TB is a systemic disease and may also commonly occur in the following 
ways;  as pleural effusion in the central nervous, lymphatic, or genitourinary systems, as 
disseminated disease (military TB). Also the infection for Mycobacterium tuberculosis can 
occur in the other body sites; in the breast, skin, or peritoneum 16,20-23. Extrapulmonary TB 
is more common in immunosuppressed persons and in young children; 
meningoencephalitis TB, lymphatic TB and military disease are particularly common in 
immunosuppressed persons, in some case the extrapulmonary TB is often accompanied 
by pulmonary TB 3, 8, 16-23.  
4. Epidemiology of TB 
TB infection is one of the most common infections in the world. It is estimated that 30-60% 
of adults in developing countries have TB infection. Annually about 8-10 million people 
develop TB disease and 2-3 million people die of the disease. TB disease is the leading cause 
of death due to infectious disease around the world 24, 25.  When the health department 
learns about a new case of TB, it should take steps to ensure that the person receives 
appropriate treatment. Is very important that the health authorities should also start a 
contact investigation, this means interviewing a person who has TB disease to determinate 
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who may have been exposed to TB, this person are screened for TB infection and disease 8, 26-
28. 
In order to the decrease in the number of TB cases reported annually is very important to 
comply three factors 29: 
 To increase federal resources for TB control and other public health efforts. 
 To improve prevention and TB control programs in state and local health department. 
 To Increase attention to ensuring that patients complete drug therapy through directly 
observed therapy (DOT). 
In the control of TB disease is also important to know the Groups at High Risk for TB 29, 30: 
People at Higher Risk for Exposure or Infection: 
 Close contacts of people with infectious TB disease. 
 People born in areas of the world where TB is common. 
 Elderly people. 
 Low-income groups with poor access to health care, including homeless people. 
 People who inject illicit drugs. 
 People who live or work in residential facilities (Example: nursing correctional 
facilities). 
 Other people who may be exposed to TB on the job. 
 People in other groups as identified by local public health officials. 
People at Higher Risk for TB disease: 
 People with other medical conditions that can increase the risk for TB. 
 People recently infected with Mycobacterium tuberculosis. 
 People with chest x-ray  suggestive of previous TB disease. 
 People who inject illicit drugs. 
 People with HIV infection. 
Infection with HIV makes people susceptible to rapidly progressive tuberculosis; over 10 
millions peoples are infected with both HIV and Mycobacterium tuberculosis 8. 
TB in Children:  
The occurrence of TB infection and disease in children provide important information about 
the spread of TB in homes and communities. When a child has TB infection or disease is 
important to learn if 29-31 : 
 Recent TB transmition. 
 Other adults and children in the household or community have probably been exposed 
to TB; if they are infected, they may develop TB disease in the future. 
4.1 Drug-resistant tuberculosis 
Drug-resistant TB is transmitted in the same way as drug-susceptible TB. The earlier outbreaks 
of multidrugs-resistant (MDR) TB support the findings that drug-resistant TB is no less 
infectious than drug-susceptible TB, although prolonged periods of infectiousness that often 
occur in the patients with drug-resistant TB may facililate transmission. Drug resistance was 
divided in two types; primary resistance and secondary or acquired resistance. Primary 
resistance develops in persons who are initially infected, with resistant organisms. Second 
resistance, or acquired resistance develops during TB therapy, either because the patient was 
treated with an inadequate regimen or because the patient did not take the prescribed regimen 
appropriately 27, 29, 32.  The MDR-TB are resistant to rifampicin and isoniazid drugs. Recently 
drug-resistant tuberculosis (XDR-TB) is defined as tuberculosis caused by a Mycobacterium 
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tuberculosis strain that is resistant to at least rifampicin and isoniazid among the first-line 
antitubercular drugs (MDR-TB) in addition to resistance to any fluroquinolones and at least 
one of three  second-line drugs, namely amikacin, kanamycin and/or capreomycin. Current 
studies have described XDR-TB strains from all continents. Worldwide prevalence of XDR-TB 
is estimated in 6.6% in all the studied countries among MDR-TB strains. The emergence of 
XDR-TB strains is a reflection of poor tuberculosis management, and controlling its emergence 
constitutes an urgent global health reality and a challenge to tuberculosis control activities in 
all parts of the world, especially in developing countries and those lacking resources and as 
well as in countries with increasing prevalence of HIV/AIDS 32-34 . 
5. Diagnosis of tuberculosis 
The systemic symptom of Tuberculosis include fever, chills, night sweats, appetite loss, 
weigh loss, and easy fatigability,   the symptoms of pulmonary TB are productive and  
prolonged cough (>14-21 week) , chest pain and in some case the patient present 
hemoptysis. It is important to ask persons suspected of having tuberculosis about their 
history of TB exposure, infection, or disease. The clinicians may also contact the local health 
department for information about whether a patient has received tuberculosis treatment in 
the past, if the drug regimen was inadequate or if the patient may did not adhere to therapy, 
this disease may recur and may be drug resistant. Also is important to consider 
demographic factors; country of origin, age, ethnic or racial group and occupation, this 
factors may increase the patient’s risk for exposure to TB or drug-resistant TB disease.  
Clinicians should determinate whether the patient has medical conditions, especially HIV 
infection, because this infection increases the risk for TB disease. All patients who do not 
know their current HIV status should be referred for HIV counseling and testing 26, 27. 
The tuberculin skin test and the chest radiography,  are two probes  that help in the 
diagnostic for TB disease. Tuberculin skin testing useful for 29: 
 To examine a person who is not ill but may be infected with Mycobacterium tuberculosis, 
such as a person who has been exposed to someone who has TB. This test is the only 
way to diagnose tuberculosis infection before it has progressed to tuberculosis disease. 
 To determine how many people in group are infected with Mycobacterium tuberculosis. 
 To examine person who has symptoms of TB. 
A negative reaction to the tuberculin skin test does not exclude the diagnosis of TB, 
especially for patients with severe TB illness or infection with HIV. Some persons may not 
react to the tuberculin skin test if they are tested too soon after being exposed to the 
infection. Generally it takes 2-10 week after infection for a person to develop an immune 
response to tuberculin. In children younger than 6 months of age may not react to the 
tuberculin skin test because their immune systems are not yet fully developed 32. 
5.1 Chest radiography 
The chest radiography is for: 
 To detect abnormalities often seen in apical or posterior segments of upper lobe or 
superior segments of lower lobe. 
 To detect atypical images in immunosuppressed persons an in HIV-positive persons. 
In HIV-infected persons, pulmonary TB may appear in the chets radiograph. For example; 
TB disease may cause infiltrates without cavities in any lung zone, or it may cause 
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mediastinal or hiliar lymphadenophaty with or without accompanying infiltrates and/or 
cavities. In HIV-positive persons, almost any abnormality on a chest radiographic may 
indicate TB. In fact, the radiograph of an HIV-positive person with TB disease may even 
appear entirely normal. Abnormalities on chest radiographs may be suggestive of, but are 
never diagnostic of TB.  However, chest radiographic  may be used to rule out the 
possibility of pulmonary TB in a person who has a positive reaction to the tuberculin skin 
test and no symptoms of disease 29, 31, 32, 34. 
Summarizing the possibility of TB should be considered in persons who have these 
symptoms, person suspected of having this disease should be referred for a medical 
evaluation, which should include a medical history, a physical examination, a Mantoux 
tuberculin skin test or tuberculosis purified protein derivate (PPD) skin test, a chest 
radiograph. Also, it is very important any appropriate bacteriologic or histological 
examinations in this patients, principally in all inmmunosuppressed patients, of course 
including the HIV patients 29.  
Person with symptoms of TB pulmonary disease should have at least three sputum 
specimens examined by smear and culture. The bets way would be to get serial specimens 
collected early in the morning on 3 consecutive days. A health care worked should be 
prepared and directly supervise at least during the first time sputum collection. This 
personal should give properly instructed in how to produce a good specimen, the patients 
should be informed that sputum is the material brought up form the lungs and that mucus 
from the nose or throat and saliva are not good specimens 35, 36.  
Recommends for Specimen Collection: 
 Get 3 sputum specimens for smear examination and culture.  
 In persons unable to cough up sputum, induce sputum, bronchoscopy or gastric 
aspiration. 
 Before chemotherapy and drug therapy is started. 
 To use clean, sterile, one-use, plastic, disposable containers  that have been washed with 
dichromate sulfuric acid and sterilized. 
 To transport specimens to the laboratory as soon as possible. 
5.2 Laboratory examination  
Detection of acid-fast bacilli (AFB) in stained smears examined microscopically may provide 
the first bacteriologic of TB. The traditional method for to detect AFB is the Zielh-Neelsen 
coloration, it is a method more economic. There are other methods that increased sensitivity 
as fluorescent methods. Smear examination is an easy and quick procedure, because the 
results should be available within 24 hours of specimen collection. However, smear 
examination permits only the presumptive diagnosis of TB because many TB patients have 
negative AFB smears. The sensitivity of smear examination may be reduced if the directed 
inflammatory response and relative absence of cavitary lesions results in fewer organisms 
expectorated in sputum. There has been concern that the utility of sputum acid-fast smears 
may be reduced in HIV-infected populations 36, 37.  
5.3 Extrapulmonary TB disease  
This disease is not taking in account as causative agent of an extrapulmonary disease 
because the chest radiography is normal or tuberculin skin test is negative, or both. 
Mycobacteria may infect almost any organ in the body, the laboratory should expect to 
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receive a variety of extrapulmonary specimens: aseptically collected body fluids, surgically 
excised tissue, aspirated or draining pus, and urine. Others ascetically collected specimens 
are the body fluids as spinal, pleural, pericardial, synovial, ascetic, blood, pus, and bone 
marrow are aseptically collected by the physician using aspiration techniques or surgical 
procedure. Acid-fast bacilli may be difficult to isolate from some of these specimens because 
they often are diluted by the large fluid volume 16-19, 37-39.  
The identification of TB can be done by traditional culture materials include egg-based solid 
media, such as Löwenstein-Jensen medium, and synthetic solid media as Middlebrook  
7H10 and 7H11 agars. The identification depends on the visualization of mycobacterial 
colonies and is limited by the slow growth rate of these organisms. A major advance in 
laboratory diagnosis of TB has been the development of systems based on detecting growth 
in liquid media with the use of radiometric methods as Bactec System. In this, the medium 
contains palmitic acid labeled with carbon-14. The metabolism of this fatty acid by growing 
mycobacteria liberates radioactive carbon dioxide, periodic sampling of the gasses in the 
culture-containing flask permits rapid detection of mycobacterial growth 40-41.  
Species identification was accomplished with biochemical test that often involved additional 
diagnostic delays. Others techniques, currently being evaluated in a number of clinical 
settings include identification based on chromatography techniques for the studies of some 
specific lipids present in the wall of Mycobacterium 42, 43. Also genetic probes are now availed 
for the identification of Mycobacterium tuberculosis and several other common mycobacterial 
species. These probes recognize species-specific sequences of ribosomal RNA. Theoretically, 
genetic probe as polymerase chain reaction (PCR), may permit diagnosis directly form 
patients specimens, eliminating the need for culture of organism. In practice, the utility of 
PCR has been limited by problems with the sensitivity and particularly, the specificity of 
results. In some laboratories, the sensitivity and specificity have been reported to exceed 
85%. However, in several laboratories, false-positive rates ranged from 3% to 20%, and in 
one, 77% of positive results were false. In the last time the Genotype Mycobacteria Direct 
Assay (GTMD), a novel commercial assay based on nucleic acid sequence-based 
amplification technology, was evaluated for detection of Mycobacterium tuberculosis complex 
and some atypical mycobacterial species from clinical samples, and your sensitivity, 
specificity, positive predictive, and negative predictive were evaluated and these results 
were more better 44-46. 
6. Nontuberculous mycobacteria in the environment 
Environmental opportunistic mycobacteria are those that are recovered form natural and 
human influenced environments and can infect and cause disease in humans, animals, and 
birds. Other names for these mycobacteria are nontuberculous, however, they cause 
tuberculous lesions, also other name is atypical mycobacterial, it distinguish from ¨typical¨ 
Mycobacterium tuberculosis, and them nontuberculous mycobacteria (NTM). The 
environmental opportunistic mycobacteria are normal inhabitants of natural waters, 
drinking water, and soils. They can be isolated from biofilms, aerosol, and dusts. The 
distribution of NTM and the incidence of disease caused by them is perhaps are not fully 
understood in most parts of the world. NTM are widely distributed in nature and have been 
isolated from natural water, rap water, tap water, and water used in showers and surgical 
solutions 47-51. 
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It is common observation that environmental mycobacteria cause disease in individuals who 
offer some opportunity due to altered local or systemic immunity. Chronic obstructive 
pulmonary diseases, emphysema, pneumoconiosis, bronchiectasis, cystic fibrosis, thoracic 
scoliosis, aspiration due to esophageal disease, previous gastrectomy and chronic 
alcoholism  are some of conditions which have been linked to disease due to NTM. While 
the reasons may be less clear in conditions like adenitis in children, such factors may be 
quite obvious in other conditions like bronchiectasis, surgical procedures, injections, break 
in skin surface due to wounds and generalized immune deficiency states like AIDS, use of 
immunosuppressive agents as used in transplant patients, etc 50, 51. 
6.1 Pathogenesis  
The mechanisms of pathogenesis of NTM are not very clear and have not been adequately 
investigated. Very low CD4 counts and defective cytokine response have been linked to 
severe infections in AIDS patients 50.  
Nontuberculous mycobacteria have been reported to cause localized or disseminated 
disease depending on local predisposition and/or degree of immune deficit. In non-HIV 
patients, different NTM may cause localized pulmonary disease, adenitis, soft tissue 
infections, infections of joints and bones, bursae, skin ulcers and generalized disease in 
individuals like leukemia, transplant patients, etc. In AIDS patients the manifestations may 
range from localized to disseminated disease. Clinical features will include local organ 
specific signs and symptoms to persistent high grade fever, night sweats, anemia and 
weight loss in addition to nonspecific symptoms of malaise, anorexia, diarrhea, myalgia and 
occasional painful adenopathy 52-57. 
7. Epidemiology of human infection with nontuberculous mycobacteria 
The frequency of NTM pulmonary disease has been reported to be increasing on several 
continents. Changing patient populations, most notably from infection with HIV, have 
greatly increased the numbers of people at risk 57-60. Studies addressing the epidemiology of 
NTM infection may be broadly divided into three types: cutaneous delayed-type 
hypersensitivity to NTM antigens has been used to study large samples of people in many 
countries. These studies have the strength of providing information regarding simple 
infection in large groups of people but suffer from the lack of information regarding the 
prevalence of disease. Another drawback of this study type reflects the relatively poor 
specificity of the skin test, as well as overlap in reactivity among various Mycobacterial 
species. The second useful type of epidemiologic study of NMT infection includes 
investigations reviewing consecutive isolates from a mycobacterial laboratory. In the 
presence of adequate laboratory protocols to avoid contamination with environmental 
organisms, these studies provide unequivocal evidence of infection but have the obvious 
shortcoming of a lack of clinical data, preventing the assessment regarding the presence or 
absence of disease. The final and most useful study type combines information from the 
mycobacterial laboratory and the clinician’s assessment 55-62.  
A true increase in rates of infection and disease could be related to the host, the pathogen, or 
some interaction between the two. Host changes leading to increased numbers of 
susceptibility could play an important role, with increased numbers of patients with 
inadequate defenses from diseases such as HIV infection, malignancy, or simply advanced 
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age. Many investigations have observed decreasing rates of TB concomitant with the 
increases in NTM. Finally, an interaction between the host and pathogen could involve a 
major increase in pathogen exposure or potential inoculum size 63-67.  
7.1 Clinical manifestations  
Environmental opportunist or nontuberculous mycobacteria (NMT) include both slowly 
and rapidly growing. The range of infections caused by environmental opportunist 
mycobacteria is quite broad 8, 51. 
7.2 Pulmonary infections 
Mycobacterium avium-intracellulare complex (MAC) strains have been a major cause of 
pulmonary and other infections, principally in the HIV patients. MAC infections were 
commonly seen in chronic obstructive airway disease and in the in the geriatric patients too. 
Mycobacterium kansasii and Mycobacterium scrofulaceum have been considered an important 
cause of pulmonary infections. Mycobacterium xenopi, an unusual specie has been 
encountered as a pathogen in patients with other underlying lung diseases. Others  species  
of slow grown as Mycobacterium simiae (Mycobacterium ´habana´), Mycobacterium szulgai, 
Mycobacterium  malmoense  and Mycobacterium fortuitum of rapid grown are other pathogens 
reported to be associated with pulmonary infections 51, 65-68. 
7.3 Cutaneous infection 
Mycobacterium szulgai, Mycobacterium marinum, Mycobacterium ulcerans and Mycobacterium 
vaccae have been reported to be a cause of skin infectious. Mycobacterium marinum, specie has 
been recognized as a causative organism of swimming pool granuloma or fish tank 
granuloma. It causes papular lesions in the extremities and may be confused with 
sporotricosis. Mycobacterium ulcerans is established cause of buruli ulcer, Mycobacterium 
vaccae has also been reported to be a cause of skin infections 51-56.   
7.4 Wound infection bone, joints and bursae and sepsis 
Mycobacterium fortuitum causes pyogenic lesions in the soft tissue, joints, bursae and 
injection abscesses, while Mycobacterium chelonae abscessus is a well known cause of wound 
infections, a new related species Mycobacterum immunogenum has been recently been 
recognized as a cause of sepsis. Mycobacterium marinum also causes infections of bones, 
joints, tendon sheaths especially in AIDS patients. Mycobacterium smegmatis, and more 
recently Mycobacterium wolinskyi and Mycobacterium thermoresistible have been reported to 
cause wound infection and also bacteraemia. Mycobacterium terrae complex (Mycobacterium 
terrae, Mycobacterium nonchromogenicum and Mycobacterium triviale) may be associated with 
mycobacterial disease. Also occasionally Mycobacterium nonchromogenicum and 
Mycobacterium chelonae have been identified as causes of acupuncture induced infections. 
Mycobacterium septicum a new rapidly growing species has been reported to be associated 
with catheter related bacteremia 49, 51, 57,58.  
7.5 Lymphadenitis 
Infection of the submaxillar, cervical, inguinal or preauricular lymph nodes is the most 
common presentation of NTM lymphadenitis. The involved lymph nodes are generally 
unilateral (95%) and not tender 54-57. The nodes may enlarge rapidly, and even rupture, with 
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formation of sinus tracts that result in prolonged local drainage. Other nodal groups outside 
of the head and neck may be involved occasionally. Distinguishing tuberculous from 
nontuberculous lymphadenitis is key because the former requires drug therapy and public 
health tracking, whereas the latter does not. A definitive diagnosis of NTM lymphadenitis is 
made by recovery of the causative organism form lymph node cultures. A simple diagnostic 
biopsy or incision and drainage of the involved lymph nodes should be avoided, since most 
of these procedures will be followed by fistulae formation with chronic drainage. However, 
even with excised nodes with compatible histopathology, only about 50% will yield positive 
cultures, because in some case these smear-positive, culture-negative cases may be due to 
fastidious species such as Mycobacterium haemophilum or Mycobacterium genavence. 
Approximately 80% of culture-proven cases of NTM lymphadenitis are due to MAC. It´s 
predominance is due to a change approximately from 20-30 years ago, when most 
geographic areas reported Mycobacterium scrofulaceum as the most common etiologic agent, 
only about 10% of the culture-proved mycobacterial cervical lymphadenitis in children is 
due to Mycobacterium avium  complex and Mycobacterium scrofulaceum. Also Mycobacterium 
haemophilum, Mycobacterium malmoense, Mycobacterium fortuitum and others have been 
isolated from cases of lymphadenitis including HIV patients. In contrast, in adults more 
than 90% of the culture-proven mycobacterial lymphadenitis is due to Mycobacterium 
tuberculosis  8, 67, 70-76. 
7.6 Disseminated disease in immunocompromized individuals 
Disseminated disease due to NTM in AIDS patients usually occurs only in those with very 
advanced immunosuppressant, because these patients frequently have other complications, 
the diagnosis of mycobacterial infection may be confused or delayed. The diagnosis is 
exceedingly rare in person with >100 CD4 cells, and it should usually be suspected only in 
persons with <50 CD4 cells 53. MAC have been found to be more commonly isolated from 
HIV-positive and HIV-negative patients, in their the portal of entry mainly through the gut 
31  67,69. Persistent high grade fever, night sweats, anemia and weight loss in addition to 
nonspecific symptoms of malaise, anorexia, diarrhoea, myalgia and occasional 
painfuladenopathy are common signs and symptoms associated with MAC disease in AIDS 
cases. Others pulmonary and extrapulmonary mycobacterial infections in AIDS patients are 
for  Mycobacterium kansasii , Mycobacterium scrofulaceum, Mycobacterium xenopi, Mycobacterium 
simiae, Mycobacterium fortuitum-Mycobacterium chelonei complex, Mycobacterium malmoense, 
Mycobacterium szulgai, and more recently Mycobacterium genavense, Mycobacterium 
haemophilum and Mycobacterium celatum 74-82. 
8. Identification of nontuberculous mycobacteria 
Traditional identification of NTM, as well as Mycobacterium tuberculosis, has relied upon 
statistical probabilities of presenting a characteristic reaction pattern in battery biochemical 
test. The niacin test was the most useful for separating NTM and Mycobacterium tuberculosis 
because the former is usually negative, whereas isolates of  Mycobacterium tuberculosis  are 
positive. Runyon devised the first good scheme for grouping NTM based on growth rates 
and colony pigmentation. For the diagnostic of NTM is very important to know the growth 
rates  and  colony pigmentation, and biochemical test such as,  niacin production, nitrate 
reduction, tween-80 hydrolysis, arylsulphatase, urease, tellurite reduction, catalase 
www.intechopen.com
Infection for Mycobacterium tuberculosis and  
Nontuberculous Mycobacteria in the HIV/AIDS Patients   
 
13 
qualitative and quantitative, grown on MaConkey agar, sodium chloride tolerance, etc, are 
adequate to identify majority of clinically relevant mycobacteria. This strategy is very 
necessary and important for the diagnostic of NTM, however, some time consuming and is 
not conclusive for many isolates with variable characters. For this reason others  alternative 
diagnostic techniques are recommended, for example, the analysis of the mycolic acids of 
mycobacteria by thin layer chromatography (TLC) and high performance liquid 
chromatography (HPLC), and more recently the identification and characterization of NTM 
by molecular methods, based on new knowledge about the gene sequences of mycobacteria 
many gene probes for the identification of isolates as well as amplification of specific gene 
fragments from the lesions and mycobacterial culture isolates have  been developed; gene 
probes, polymerase chain reaction (PCR) techniques, DNA fingerprinting techniques, etc, 35-
40, 43,44,48, 83, 84 
9. Mycobacterium tuberculosis and nontuberculous mycobacteria diseases 
in the HIV/AIDS patients 
After years of worldwide decline of tuberculosis (TB), this disease has returned as a big 
problem in the Public Health. The resurgence of TB in the past decades is closely linked to 
acquired immunodeficiency syndrome (AIDS) pandemic. The high susceptibility of patients 
infected with the human immunodeficiency virus (HIV) to TB and others mycobacterial 
infections is unique, creating a lot of diagnostic and therapeutic challenges for clinicians 
12,32,24. Pulmonary tuberculosis is the most common manifestation of tuberculosis in adults 
infected with HIV 53,85,86.  
HIV/TB co-infection occurs in various stages of HIV infection, with the clinical pattern 
correlating with the patient’s immune status. In the early stages of HIV infection, when 
immunity is only partially compromised, the features are more typical of tuberculosis, 
commonly with upper lobe cavitations, and the disease resembles that seen in the pre-HIV 
era. HIV-infected patients present with atypical pulmonary disease due to immune 
deficiency advances, resembling primary tuberculosis or extra pulmonary and disseminated 
disease, commonly with hilar adenopathy and lower lobe infection 87. 
9.1 Clinical symptoms in pulmonary tuberculosis 
The clinical symptoms are severally similar in HIV-infected and HIV-negative patients. 
However, cough is reported less frequently by HIV-infected patients, probably because 
there is less cavitations, inflammation and endobronchial irritation as a result of a reduction 
in cell-mediated immunity. Similarly, haemoptysis, which results from caseous necrosis of 
the bronchial arteries, is less common in HIV-infected patients 87.88. 
In general, the traits that characterize HIV-TB co-infection include the potential for rapid 
progression from primary infection to disseminated disease, atypical radiographic features 
of pulmonary disease, increased frequency of extrapulmonary disease and involvement of 
unusual sites of infection. All of these atypical features seem to occur more commonly with 
more advance stages of immunosuppression and the paradigm that emerges is one of 
typical TB early in the course of HIV infection and atypical manifestation with advanced 
HIV disease, in this case the atypical features included lower lobe alveolar opacities, 
multifocal alveolar opacities, interstitial infiltrates, mediastinal adenopathy and pleural 
effusions 24,30,67,69,89. 
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9.2 Clinical symptoms in extrapulmonary tuberculosis 
The main manifestation of extrapulmonary tuberculosis in AIDS patients are 
lymphadenopathy, pleural effusion, meningitis, pericardial effusion and miliary 
tuberculosis. This diagnostic is often difficult because the patients with HIV are prone to all 
of the usual bacterial and viral infection that affect a non-HIV infected patients, so, the 
presentation of extrapulmonary tuberculosis in HIV-infected patients is generally no 
different 8, 69. 
9.3 Nontuberculous mycobacterial infection in HIV/AIDS patients 
The clinical relevant of NMT infection in HIV/AIDS patients are very frequent, this 
infection can be pulmonary and extrapulmonary and their symptoms are the same that 
Mycobacterium tuberculosis 51-54, 69. Recently, the nontuberculous mycobacterial are also 
denominated as environmental opportunist mycobacterial. Normally, they live as 
environmental saprophytes and they cause opportunist disease in human. Many cases of 
NTM are associated with some form of immune deficiency in special HIV/AIDS patients. In 
this group of patients is frequently to find this mycobacterial species as etiological agent for 
this reason is very important their microbiology diagnostic which is different to 
Mycobacterium tuberculosis 90, 91.  
Disseminate Mycobacterium avium complex (MAC) diseases was one of the first opportunist 
infections recognized in the syndrome of AIDS since 20 years ago. The interest of the 
diagnostic of disseminated MAC and others species of nontuberculous mycobacteria 
infection have been increased as a result of the HIV pandemic. The prevention and 
treatment in nontuberculous mycobacteria are life long because cure of them were not 
achievable in AIDS patients with profound immune suppression. The precise immune 
defect predisposing HIV/AIDS patients to disseminated diseases is unknown 92 . 
The main manifestation of pulmonary and extrapulmonary infections for Mycobacterium 
tuberculosis  and nontuberculous mycobacterial are the same affecting lung, pleura, skin, 
lymphatic system and producing dissemination infection (Figure 1, Figure 2), (Figure 3A-
3B-3C, Figure 4A-4B) 8, 63,69.  For this reason is very important the highly active antiretroviral 
therapy (HAART) for treatment of AIDS patients that has been associated with a market 
reduction in the incidence of most opportunistic infection 82,89,92. 
So, is very important that the mycobacteriology laboratory should give a definitive 
diagnostic,  because in immunosuppressed patients is important to find resistant alcohol 
acid bacillus in order to detect the co-infection with Mycobacterium tuberculosis which is the 
most frequently agent found. Nevertheless, others species of mycobacteria may be causing 
infection and should be search for. 
 
 
Fig. 1. Messenteric lymph nodes for Mycobacterium tuberculosis in AIDS patients. 
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Fig. 2. Biopsy of liver pedicle lymph nodes for Mycobacterium tuberculosis in AIDS patients. 
 
                 
          A           B              C 
Fig. 3. AIDS patients with skin lesions from Mycobacterium avium complex (Figure 3A, Figure 
3B) and Mycobacterium fortuitum (Figure 3C)  
 
                                 
          A           B              C 
Fig. 4. Lymphadenitis cervical from Mycobacterium tuberculosis (Figure 4A), inguinal-testes 
lesions from Mycobacterium avium complex in lymphatic system (Figure 4B, Figure 4C). 
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